Epidermolysis Bullosa, Junctional
7
4
4
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
14.3%
1 terminated out of 7 trials
50.0%
-36.5% vs benchmark
29%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa
Computational Drug Repurposing for All EBS Cases
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)